Reducing the pain: A cost-effectiveness analysis of transversus abdominis plane block using liposomal bupivacaine for outpatient laparoscopic ventral hernia repair

•A decision tree was constructed to determine cost-effectiveness as measured by incremental cost-effectiveness ratios (ICER) per quality-adjusted life-year (QALY).•The liposomal bupivacaine TAP block was a dominant strategy yielding a $456.75 decrease in cost and an 0.1 increase in QALYs relative to opioids alone.•In 1-way sensitivity analysis of cost, ICER values were most sensitive to variations in the amount saved by SDD and the cost of bupivacaine.•In probabilistic sensitivity analyses, TAP strategy was cost-effective at a willingness-to-pay threshold of $50,000/QALY in 94.5% of iterations and pay threshold of $100,000/QALY in 97.1% of iterations.